ABOUT US
We are a late-stage medical aesthetics company developing a novel injectable treatment targeting focal fat reduction for body contouring. Our lead asset 10XB101, is a best in class injectable that has demonstrated impressive P2 results showing superior efficacy and better tolerability than currently marketed products.
PRODUCTS
Our lead drug product, 10XB101, is a novel formulation of polidocanol, a well known medical detergent used in sclerotherapy with a long history of safety. 10XB101 is being developed for submental fat contouring and flank contouring. Results demonstrate a rapid onset of efficacy with minimal side effects. See corporate presentation for more details.
PEOPLE
Ted White
CEO
Novartis
Aqua Pharmaceuticals an Almirall Co
Verrica
Gary Goldenberg, M.D.
Chief Medical Officer
Icahn School of Medicine Mount Sinai
Goldenberg Dermatology
Verrica
Deepak Chadha
Chief Development Officer
Allergan
Kythera
John Dobak, M.D.
Executive Chair and Co-Founder
CEO, ClicBio, Inc.
Dan Piacquadio, M.D.
Board Member and Co-Founder
CEO, Therapeutics, Inc.
NEWSROOM
Get the most recent updates.
Recent Press Releases
(Leios Therapeutics, Inc., formerly operated as 10xBio, LLC)
10xBio Announces Data from Interim Analysis of Phase 2b Clinical Trial Showing Superior Efficacy of Novel Drug for Submental Body Contouring
March 11, 2024
10xBio Announces the Completion of Enrollment In Phase 2b Clinical Trial of Novel Drug For Submental Body Contouring
August 16, 2023
10xBio Provides Update on Patent Portfolio
July 15, 2023
CONNECT
Thank you for your interest. Complete the form below and we will get back to you soon.